Montelukast

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 19.04.2021

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Pharmacodynamics (Effect)
This section has been translated automatically.

Montelukast binds to the cysteinyl leukotriene 1 receptor, thus preventing the binding of leukotriene to this receptor, interrupting the leukotriene-mediated inflammatory reaction (the binding of leukotriene to the cysteinyl leukotriene 1 receptor leads to edema formation, damage to the bronchial epithelium and bronchoconstriction, resulting in narrowing of the airways due to bronchial muscle contraction).

Indication
This section has been translated automatically.

  • Supplementary therapy for mild to moderate chronic bronchial asthma that cannot be adequately treated with inhaled corticosteroids or adequately controlled by the use of short-acting beta-sympathomimetics as needed. Prophylaxis of exercise-induced asthma (asthma during physical exercise).

Remember! Not approved for the treatment of acute asthma attacks.

Pregnancy/nursing period
This section has been translated automatically.

Strict benefit-risk assessment (insufficient data available)!

Dosage and method of use
This section has been translated automatically.

  • Adults: 1 time a day 10 mg p.o. before bedtime.
  • Children/teenagers 6-14 LJ: once/day 5 mg p.o. before bedtime.
  • Children 2-5 LJ: once/day 4 mg p.o. before bedtime.

Undesirable effects
This section has been translated automatically.

  • In young children: Occasionally: Diarhoea, hyperactivity, asthma, skin changes like dermatitis, thirst.
  • In adolescents/adults: headache, stomach ache.

Interactions
This section has been translated automatically.

Drugs that induce increased activity of cytochrome P450 3A4; in particular phenytoin, rifampicin, phenobarbital, cause a reduction in the bioavailability of montelukast.

Preparations
This section has been translated automatically.

Singulair®

Note(s)
This section has been translated automatically.

Effect begins as early as 1 day after the start of therapy; therapy should be continued if there are no symptoms and if the condition worsens.

Authors

Last updated on: 19.04.2021